)
10X Genomics (TXG) investor relations material
10X Genomics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q2 2026 revenue was $151M; excluding $1.6M from a Takara settlement, revenue was $149M, up 3% YoY, driven by strong consumables growth and robust demand for the Atera platform.
Acquisition of Proteintech Genomics for $6.1M in cash to enhance proteomics and multi-omics capabilities.
Strong customer response and high order volume for Atera, with demand exceeding expectations and broad application across disease areas.
AI adoption is driving demand for single-cell and spatial technologies across academia and biopharma.
Multi-year research collaborations announced with Cleveland Clinic and Lausanne University Hospital for oncology biomarker research.
Financial highlights
Consumables revenue grew 7% YoY, while instrument revenue declined 47% YoY; services revenue rose 26%.
Gross margin improved to 74% from 72% YoY, aided by lower manufacturing costs and tariff refunds.
Operating expenses were $132.1M, nearly flat YoY when excluding litigation settlement gains.
Net loss for Q2 2026 was $17.9M, compared to net income of $34.5M in Q2 2025.
Cash, equivalents, and marketable securities totaled $552M as of June 30, 2026.
Outlook and guidance
Full-year 2026 revenue guidance raised to $610M–$630M, representing 2–5% growth over 2025, excluding non-recurring items.
Expect to ship ~40 Atera instruments in 2026, with most shipments in Q4; booked orders already exceed this number.
Q3 revenue expected to see a modest sequential step down due to spatial product transition, with a significant Q4 step up as Atera ramps.
Guidance assumes no improvement in the macro environment or academic funding flows.
Operating expenses (excluding settlements) are expected to modestly decrease in 2026 due to ongoing cost management.
- Q4 revenue beat guidance, consumables surged, losses narrowed, and 2026 growth is projected at 0–4%.TXG
Q4 202514 Jul 2026 - Q3 2024 revenue fell 1% as spatial growth offset weak instruments; guidance was lowered.TXG
Q3 20248 Jul 2026 - Q2 revenue up 4% to $153.1M; guidance lowered amid macro headwinds and strong consumables demand.TXG
Q2 20248 Jul 2026 - Atera's launch drives strong demand and positions the company for future growth and innovation.TXG
Bank of America Global Healthcare Conference 202614 May 2026 - Q1 revenue up 9% adjusted, gross margin at 70%, and Atera launch drives strong demand.TXG
Q1 20268 May 2026 - 2026 proxy covers director elections, auditor ratification, and executive pay, with strong governance focus.TXG
Proxy filing24 Apr 2026 - Director elections, auditor ratification, and executive pay are up for vote at the annual meeting.TXG
Proxy filing24 Apr 2026 - Atera delivers high-throughput, single-cell spatial transcriptomics with unmatched flexibility.TXG
Corporate presentation19 Apr 2026 - Innovation and strong cash flow drive growth amid macro challenges and evolving customer needs.TXG
TD Cowen 46th Annual Health Care Conference3 Mar 2026
Next 10X Genomics earnings date
Next 10X Genomics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage